Related Experiment Video
Updated: Sep 25, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Tofacitinib: An Option for Acute Severe Ulcerative Colitis?
Sara Santos1, Verónica Gamelas1, Rita Saraiva1
1Centro Hospitalar de Lisboa Central, Lisbon, Portugal.
Tofacitinib offers a new rescue therapy option for severe ulcerative colitis (UC) cases. This JAK inhibitor shows promise for patients with difficult-to-treat disease and limited treatment alternatives.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis (UC) management is challenging, especially in acute severe episodes (ASUC).
- Limited therapeutic options exist for ASUC patients with long disease duration and prior treatment failures.
- New pharmacological interventions are needed for refractory ASUC.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

